ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
January 20, 2022Omeros Corporation (Nasdaq: OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency's Complete Response Letter (CRL) for narsoplimab... -
Omeros reports positive results for Narsoplimab in treatment of Covid-19-associated ARDS
August 13, 2020Omeros Corporation reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) ... -
Omeros, Lonza Enter Commercial Manufacturing Agreement
August 01, 2019Builds on existing clinical supply deal for narsoplimab.
Pharma Sources Insight January 2025
